Inadequacy of remote desktop interface for independent reanalysis of data from drug trials

We write on behalf of a team that has taken on the task of rewriting GlaxoSmithKline’s Study 329 of paroxetine in adolescents under the RIAT (restoring invisible and abandoned trials) project.1 2 GSK granted our RIAT team access to the data from the Paxil Study 329 to do an independent reanalysis, and we’ve now had months of experience working with their “remote desktop” interface as a portal to their information. It is a single windowed multiple document interface, totally self contained, which cannot be accessed by software other than that provided inside the window. Multiple passwords are needed multiple times for access, and some …